PT-141 (Bremelanotide): reference dosing schedule
Human schedule
PT-141 (bremelanotide) is given subcutaneously on demand, a single dose ahead of an event rather than as a course. Generalized from clinical studies (RECONNECT) and the label of the approved product Vyleesi.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Starting (to gauge tolerability) | 0.5–1 mg subcutaneously, on demand, ≥45 min before the event | Starting dose |
| Studied regimen (Vyleesi) | 1.75 mg subcutaneously, single dose on demand | Increase if needed |
| Frequency limit | no more than 1 dose per 24 h; up to 8 doses per month | Maximum in this schedule |